335 related articles for article (PubMed ID: 34299000)
21. Potential of the cannabinoid CB(2) receptor as a pharmacological target against inflammation in Parkinson's disease.
Gómez-Gálvez Y; Palomo-Garo C; Fernández-Ruiz J; García C
Prog Neuropsychopharmacol Biol Psychiatry; 2016 Jan; 64():200-8. PubMed ID: 25863279
[TBL] [Abstract][Full Text] [Related]
22. Progressive loss of dopaminergic neurons induced by unilateral rotenone infusion into the medial forebrain bundle.
Norazit A; Meedeniya AC; Nguyen MN; Mackay-Sim A
Brain Res; 2010 Nov; 1360():119-29. PubMed ID: 20807515
[TBL] [Abstract][Full Text] [Related]
23. TLR4 deficiency has a protective effect in the MPTP/probenecid mouse model of Parkinson's disease.
Shao QH; Chen Y; Li FF; Wang S; Zhang XL; Yuan YH; Chen NH
Acta Pharmacol Sin; 2019 Dec; 40(12):1503-1512. PubMed ID: 31388087
[TBL] [Abstract][Full Text] [Related]
24. Castration induces Parkinson disease pathologies in young male mice via inducible nitric-oxide synthase.
Khasnavis S; Ghosh A; Roy A; Pahan K
J Biol Chem; 2013 Jul; 288(29):20843-20855. PubMed ID: 23744073
[TBL] [Abstract][Full Text] [Related]
25. Exercise in an animal model of Parkinson's disease: Motor recovery but not restoration of the nigrostriatal pathway.
Churchill MJ; Pflibsen L; Sconce MD; Moore C; Kim K; Meshul CK
Neuroscience; 2017 Sep; 359():224-247. PubMed ID: 28754312
[TBL] [Abstract][Full Text] [Related]
26. Progressive nigrostriatal terminal dysfunction and degeneration in the engrailed1 heterozygous mouse model of Parkinson's disease.
Nordströma U; Beauvais G; Ghosh A; Pulikkaparambil Sasidharan BC; Lundblad M; Fuchs J; Joshi RL; Lipton JW; Roholt A; Medicetty S; Feinstein TN; Steiner JA; Escobar Galvis ML; Prochiantz A; Brundin P
Neurobiol Dis; 2015 Jan; 73():70-82. PubMed ID: 25281317
[TBL] [Abstract][Full Text] [Related]
27. Anesthetic Effects on the Progression of Parkinson Disease in the Rat DJ-1 Model.
Xu DA; DeYoung TP; Kondoleon NP; Eckenhoff RG; Eckenhoff MF
Anesth Analg; 2021 Nov; 133(5):1140-1151. PubMed ID: 34673725
[TBL] [Abstract][Full Text] [Related]
28. Running exercise protects the substantia nigra dopaminergic neurons against inflammation-induced degeneration via the activation of BDNF signaling pathway.
Wu SY; Wang TF; Yu L; Jen CJ; Chuang JI; Wu FS; Wu CW; Kuo YM
Brain Behav Immun; 2011 Jan; 25(1):135-46. PubMed ID: 20851176
[TBL] [Abstract][Full Text] [Related]
29. Further characterisation of the LPS model of Parkinson's disease: a comparison of intra-nigral and intra-striatal lipopolysaccharide administration on motor function, microgliosis and nigrostriatal neurodegeneration in the rat.
Hoban DB; Connaughton E; Connaughton C; Hogan G; Thornton C; Mulcahy P; Moloney TC; Dowd E
Brain Behav Immun; 2013 Jan; 27(1):91-100. PubMed ID: 23044176
[TBL] [Abstract][Full Text] [Related]
30. Somatostatin prevents lipopolysaccharide-induced neurodegeneration in the rat substantia nigra by inhibiting the activation of microglia.
Bai L; Zhang X; Li X; Liu N; Lou F; Ma H; Luo X; Ren Y
Mol Med Rep; 2015 Jul; 12(1):1002-8. PubMed ID: 25777539
[TBL] [Abstract][Full Text] [Related]
31. Selective microglial activation in the rat rotenone model of Parkinson's disease.
Sherer TB; Betarbet R; Kim JH; Greenamyre JT
Neurosci Lett; 2003 May; 341(2):87-90. PubMed ID: 12686372
[TBL] [Abstract][Full Text] [Related]
32. Intrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration.
Paumier KL; Luk KC; Manfredsson FP; Kanaan NM; Lipton JW; Collier TJ; Steece-Collier K; Kemp CJ; Celano S; Schulz E; Sandoval IM; Fleming S; Dirr E; Polinski NK; Trojanowski JQ; Lee VM; Sortwell CE
Neurobiol Dis; 2015 Oct; 82():185-199. PubMed ID: 26093169
[TBL] [Abstract][Full Text] [Related]
33. Neuroprotective potential of ferulic acid in the rotenone model of Parkinson's disease.
Ojha S; Javed H; Azimullah S; Abul Khair SB; Haque ME
Drug Des Devel Ther; 2015; 9():5499-510. PubMed ID: 26504373
[TBL] [Abstract][Full Text] [Related]
34. D-Ala2-GIP-glu-PAL is neuroprotective in a chronic Parkinson's disease mouse model and increases BNDF expression while reducing neuroinflammation and lipid peroxidation.
Li Y; Liu W; Li L; Hölscher C
Eur J Pharmacol; 2017 Feb; 797():162-172. PubMed ID: 27913104
[TBL] [Abstract][Full Text] [Related]
35. CX3CR1 Disruption Differentially Influences Dopaminergic Neuron Degeneration in Parkinsonian Mice Depending on the Neurotoxin and Route of Administration.
Tristão FS; Lazzarini M; Martin S; Amar M; Stühmer W; Kirchhoff F; Gomes LA; Lanfumey L; Prediger RD; Sepulveda JE; Del-Bel EA; Raisman-Vozari R
Neurotox Res; 2016 Apr; 29(3):364-80. PubMed ID: 26403659
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of Rho-kinase by Fasudil protects dopamine neurons and attenuates inflammatory response in an intranasal lipopolysaccharide-mediated Parkinson's model.
He Q; Li YH; Guo SS; Wang Y; Lin W; Zhang Q; Wang J; Ma CG; Xiao BG
Eur J Neurosci; 2016 Jan; 43(1):41-52. PubMed ID: 26565388
[TBL] [Abstract][Full Text] [Related]
37. The efficacy of systemic administration of lipopolysaccharide in modelling pre-motor Parkinson's disease in C57BL/6 mice.
Deng I; Wiese MD; Zhou XF; Bobrovskaya L
Neurotoxicology; 2021 Jul; 85():254-264. PubMed ID: 34097939
[TBL] [Abstract][Full Text] [Related]
38. Riluzole neuroprotection in a Parkinson's disease model involves suppression of reactive astrocytosis but not GLT-1 regulation.
Carbone M; Duty S; Rattray M
BMC Neurosci; 2012 Apr; 13():38. PubMed ID: 22480308
[TBL] [Abstract][Full Text] [Related]
39. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
[TBL] [Abstract][Full Text] [Related]
40. Progression of intestinal permeability changes and alpha-synuclein expression in a mouse model of Parkinson's disease.
Kelly LP; Carvey PM; Keshavarzian A; Shannon KM; Shaikh M; Bakay RA; Kordower JH
Mov Disord; 2014 Jul; 29(8):999-1009. PubMed ID: 24898698
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
